Literature DB >> 10975596

Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.

L Djandjighian1, J Planchenault, O Finance, G Pastor, P Gautier, D Nisato.   

Abstract

The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction. All dogs (n = 6) randomly received orally dronedarone (10 and 30 mg/kg), amiodarone (10 and 30 mg/kg), and placebo twice daily for 7 days, with a 3-week washout between consecutive treatments. Heart rate (HR), mean arterial pressure (MBP), positive rate of increase of left ventricular pressure (+LVdP/dt), echocardiographically assessed left ventricular ejection fraction (LVEF), and fractional shortening (FS), as well as chronotropic response to isoproterenol and exercise-induced sympathetic stimulation were evaluated under baseline and posttreatment conditions. Resting values of LVEF, FS, +LVdP/dt, and MBP remained unchanged whatever the drug and the dosing regimen, whereas resting HR was significantly and dose-dependently lowered after dronedarone and to a lesser extent after amiodarone. Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia. Thus, dronedarone and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function. Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias, without compromising the left ventricular function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975596     DOI: 10.1097/00005344-200009000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 2.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

3.  Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation.

Authors:  Renee M Sullivan; Brian Olshansky
Journal:  Core Evid       Date:  2010-10-21

4.  Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.

Authors:  Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez
Journal:  Clin Med Insights Cardiol       Date:  2011-10-06

5.  Short-term effects of oral dronedarone administration on cardiac function, blood pressure and electrocardiogram in conscious telemetry dogs.

Authors:  Nakkawee Saengklub; Brad Youngblood; Carlos Del Rio; Suwanakiet Sawangkoon; Robert L Hamlin; Anusak Kijtawornrat
Journal:  J Vet Med Sci       Date:  2016-02-26       Impact factor: 1.267

Review 6.  Dronedarone for atrial fibrillation: a new therapeutic agent.

Authors:  Pawan D Patel; Rohit Bhuriya; Dipal D Patel; Bhaskar L Arora; Param P Singh; Rohit R Arora
Journal:  Vasc Health Risk Manag       Date:  2009-08-06

Review 7.  Novel anti-arrhythmic medications in the treatment of atrial fibrillation.

Authors:  Pradyot Saklani; Allan Skanes
Journal:  Curr Cardiol Rev       Date:  2012-11

8.  The effect of long-term amiodarone administration on myocardial fibrosis and evolution of left ventricular remodeling in a porcine model of ischemic cardiomyopathy.

Authors:  Anastasia Zagorianou; Meletios Marougkas; Stavros G Drakos; Nikolaos Diakos; Panagiotis Konstantopoulos; Despina N Perrea; Maria Anastasiou-Nana; Konstantinos Malliaras
Journal:  Springerplus       Date:  2016-09-15

9.  Dronedarone produces early regression of myocardial remodelling in structural heart disease.

Authors:  Begoña Quintana-Villamandos; Jose Juan Gomez de Diego; María Jesús Delgado-Martos; David Muñoz-Valverde; María Luisa Soto-Montenegro; Manuel Desco; Emilio Delgado-Baeza
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.